Gilead Sciences traded at $61.73 this Friday July 1st, decreasing $0.08 or 0.13 percent since the previous trading session. Looking back, over the last four weeks, Gilead Sciences lost 2.73 percent. Over the last 12 months, its price fell by 10.92 percent. Looking ahead, we forecast Gilead Sciences to be priced at 61.38 by the end of this quarter and at 56.56 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
61.83
Daily Change
0.03%
Yearly
-10.78%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 152.26 -0.89 -0.58% 32.20%
Acorda Therapeutics 0.47 -0.001 -0.11% -89.68%
Agios Pharmaceuticals 22.85 0.68 3.07% -59.00%
ALKERMES 29.87 0.08 0.27% 18.06%
Alnylam Pharmaceuticals 147.77 1.92 1.32% -13.80%
Amgen 243.70 0.40 0.16% -2.01%
Biogen 207.00 3.06 1.50% -40.64%
Bluebird Bio 4.13 -0.01 -0.24% -86.83%
BioMarin Pharmaceutical 83.29 0.42 0.50% -2.56%
Bristol-Myers Squibb 76.23 -0.77 -1.00% 13.86%
Coherus Biosciences 7.55 0.31 4.28% -45.01%
Gilead Sciences 61.83 0.02 0.03% -10.78%
GlaxoSmithKline 1,785.60 20.00 1.13% 24.19%
Glaxosmithkline 43.32 -0.22 -0.49% 7.19%
Intercept Pharmaceuticals 13.58 -0.23 -1.66% -32.07%
Incyte Corp 76.74 0.77 1.01% -8.18%
J&J 178.08 0.57 0.32% 5.39%
Eli Lilly 320.98 -3.25 -1.00% 37.19%
Merck & Co 91.69 0.53 0.58% 16.65%
Moderna Inc 149.50 6.65 4.65% -36.20%
Neurocrine Biosciences 98.27 0.79 0.81% -0.34%
Novartis 80.33 -0.52 -0.64% -4.96%
Puma Biotechnology 2.73 -0.12 -4.21% -69.05%
Pfizer 51.85 -0.58 -1.11% 30.51%
PTC Therapeutics 40.99 0.93 2.32% -4.87%
Regeneron Pharmaceuticals 590.59 -0.54 -0.09% 1.19%
Sanofi 97.52 1.18 1.22% 10.94%
Sangamo BioSciences 4.19 0.05 1.21% -64.22%
Sarepta Therapeutics 74.34 -0.62 -0.83% -1.20%
Teva Pharmaceutical Industries 7.63 0.11 1.46% -22.38%
United Therapeutics 235.05 -0.59 -0.25% 27.52%
Vertex Pharmaceuticals 283.70 1.91 0.68% 41.47%

Indexes Price Day Year
US500 3799 13.81 0.36% -12.72%
USND 11001 -28.15 -0.26% -24.86%
USNDX 11521 16.86 0.15% -21.78%

Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.